Other
CapEx
Alnylam Pharmaceuticals CapEx decreased by 6.3% to $21.83M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 143.4%, from $8.97M to $21.83M. Over 4 years (FY 2021 to FY 2025), CapEx shows a downward trend with a -6.4% CAGR.
Analysis
StatementIncome Statement
SectionOther
CategoryCapital Allocation
SignalContext dependent
VolatilityModerate
First reportedQ1 2013
Last reportedQ1 2026Apr 30, 2026
How to read this metric
High levels indicate aggressive growth or maintenance investment, while low levels may signal capital efficiency or underinvestment in infrastructure.
Detailed definition
Capital expenditures represent the cash outflows used to acquire, upgrade, or maintain physical assets such as property,...
Peer comparison
Commonly reported as 'Capital Expenditures' or 'Purchases of Property, Plant, and Equipment' in the investing section of the cash flow statement.
Metric ID:
anet_capital_expendituresHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $11.25M | $26.06M | $21.89M | $17.86M | $16.06M | $16.51M | $21.64M | $13.89M | $15.92M | $17.09M | $15.31M | $12.97M | $8.02M | $4.19M | $9.09M | $8.97M | $14.29M | $12.14M | $23.29M | $21.83M |
| QoQ Change | — | +131.7% | -16.0% | -18.4% | -10.1% | +2.8% | +31.0% | -35.8% | +14.6% | +7.4% | -10.4% | -15.3% | -38.2% | -47.7% | +116.9% | -1.4% | +59.3% | -15.0% | +91.8% | -6.3% |
| YoY Change | — | — | — | — | +42.8% | -36.7% | -1.1% | -22.2% | -0.8% | +3.5% | -29.2% | -6.6% | -49.6% | -75.5% | -40.6% | -30.9% | +78.3% | +189.6% | +156.1% | +143.4% |
Range$4.19M – $26.06M
CAGR+15.0%
Avg YoY Growth+20.0%
Median YoY Growth-3.9%
CapEx at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's capex?
- Alnylam Pharmaceuticals (ALNY) reported capex of $21.83M in Q1 2026.
- How has Alnylam Pharmaceuticals's capex changed year-over-year?
- Alnylam Pharmaceuticals's capex increased by 143.4% year-over-year, from $8.97M to $21.83M.
- What is the long-term trend for Alnylam Pharmaceuticals's capex?
- Over 4 years (2021 to 2025), Alnylam Pharmaceuticals's capex has grown at a -6.4% compound annual growth rate (CAGR), from $76.37M to $58.70M.
- What does capex mean?
- Cash spent on purchasing or maintaining long-term physical assets.